<PAGE>
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB
(MARK ONE)
/X/ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended March 31, 2000
OR
/ / TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
----------- -----------
Commission file number: 0-25377
NURESCELL INC.
(NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)
NEVADA 33-0805583
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
1400 BRISTOL STREET N., SUITE 240,
NEWPORT BEACH, CALIFORNIA 92660
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
ISSUER'S TELEPHONE NUMBER: (949) 752-0071
SECURITIES REGISTERED UNDER SECTION 12(b) OF THE EXCHANGE ACT:
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
None None
SECURITIES REGISTERED UNDER SECTION 12(g) OF THE EXCHANGE ACT:
Common Stock, $.0001 par value
(TITLE OF CLASS)
Class "A" Common Stock Purchase Warrants
(TITLE OF CLASS)
Class "B" Common Stock Purchase Warrants
(TITLE OF CLASS)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or
for such shorter period that the issuer was required to file such reports), and
(2) has been subject to such filing requirements for the past 90 days.
Yes /X/ No / /
Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of issuer's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. / /
Issuer's net loss for its most recent fiscal year (ended March 31, 2000)
was $(3,986,095).
The aggregate market value of the voting and non-voting common equity held
by nonaffiliates of the issuer, based upon the average bid and asked price of
such common equity on May 31, 2000, as reported by the OTC Bulletin Board, was
approximately $10,748,000. Shares of Common Stock held by each officer and
director and by each person who owns 5% or more of the outstanding Common Stock
have been excluded in that such persons may be deemed to be affiliates. This
determination of affiliate status is not necessarily a conclusive determination
for other purposes.
The number of outstanding shares of the issuer's Common Stock on May 31,
2000 was 15,199,288.
DOCUMENTS INCORPORATED BY REFERENCE None
Transitional Small Business Disclosure Format (CHECK ONE): Yes /X/ No / /
================================================================================
<PAGE>
PART I
NOTE: NURESCELL INC. HAS ELECTED TO FOLLOW DISCLOSURE ALTERNATIVE 2 IN THE
PREPARATION OF THIS REPORT.
ITEM 6. DESCRIPTION OF BUSINESS.
THIS REPORT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING
OF SECTION 27A OF THE SECURITIES ACT OF 1933 AND SECTION 21E OF THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED. AS A RESULT OF CERTAIN FACTORS DESCRIBED BELOW
AND ELSEWHERE IN THIS REPORT, AND OTHER FACTORS, ACTUAL RESULTS COULD DIFFER
MATERIALLY FROM THOSE PROJECTED IN THOSE FORWARD-LOOKING STATEMENTS.
GENERAL. Nurescell Inc. (the "Company" or "Registrant") was formed in
Nevada on May 12, 1998 for the purpose of developing and commercially exploiting
a proprietary radiation shielding technology (the "Nurescell Technology") for
use by the nuclear power industry and others producing, handling or storing
radioactive materials. The Nurescell Technology material, which is comprised of
a unique composite of materials, is designed for incorporation into the
structural components of new and existing nuclear reactors and other facilities
in order to provide a cost-effective safeguard from the lethal effect of
radiation while achieving a minimal disruption to existing facilities. It is
also designed as a containment material which will provide an attractive
alternative to the conventional technologies currently used to transport and
store ever-increasing amounts of spent nuclear fuel and other radioactive waste.
In addition, it is expected to provide an innovative shielding material for
various other purposes, including nuclear accelerator and defense research
applications. The Nurescell Technology is based upon a proprietary formulation
which was acquired from Adrian A. Joseph, Ph.D., the Company's Chief Executive
Officer and majority shareholder, in June 1998. See "Item 11. Interest of
Management and Others in Certain Transactions." The intended market for the
Company's products includes nuclear power plants, healthcare facilities,
accelerators and waste transport and storage facilities worldwide. Based on the
potential applications for the Nurescell Technology, as well as the potential
markets, the Company believes that there is an opportunity to develop a
profitable business over the next two years. However, because the Company is in
its pre-production and testing stage, it currently has only limited sales, and
is not extensively marketing the Nurescell Technology. As a result, there can be
no assurance that the Company or the Nurescell Technology will be successful or
that the Company can or will achieve any substantial sales or profitability.
THE PRODUCTS. Since inception, the Company has spent approximately $150,000
on research and development activities with respect to the Nurescell Technology.
Upon completion of testing, the Nurescell Technology is expected to be superior
to existing and competing technology. It is believed that products based on the
Nurescell Technology will possess characteristics which include:
- favorable heat transfer and diffusion properties;
- high radioactive resistance, including blockage of neutrons and
shielding against alpha, beta and gamma radiation;
- high compressive and tensile strengths;
- corrosion and shrinkage resistance;
- fugitive gassing properties;
- resistance to weathering and aging;
- ease of application and handling; and
- a non-hazardous application process.
In addition, the Company's products are expected to result in significant
reductions in the weight and volume of encapsulated nuclear waste and/or on-site
spent fuel depository space. If achieved, those characteristics are believed by
the Company to be superior to ceramic silicon foam, lead, steel or concrete that
are used today in the industry, and thus correct some of the most acute problems
associated with conventional nuclear materials and the resultant radioactive
waste problems. In addition, the physical performance characteristics of the
Nurescell Technology material is expected to expedite advances in nuclear
accelerator and innovative fuel projects, which require special performance
materials for their facilities.
-2-
<PAGE>
For the past year, the University of Missouri has been testing the
Company's material with respect to high levels of alpha, beta and gamma
radiation. At this point, the Nurescell Technology material has successfully
completed radiation testing to 10 Grad without any physical deterioration, a
much higher level than would be encountered in a nuclear power plant (with
"Grad" standing for one billion roentgen, which are units of measurement for
radioactivity). The Company has also completed certain testing of its new
spray-on radiation and corrosion resistant formulant of the Nurescell Technology
material through the Julich Institute in Germany.
After the completion of all attenuation testing of the Nurescell
Technology, the Company will seek to qualify the Nurescell Technology material
for specialized applications and into bench scale and field trials of
specialized private enterprise equipment.
THE MARKET. The Company considers every nuclear power plant in the world to
be a potential customer for the Nurescell Technology which, because of its
mechanical properties (including structural strength), can be used in materials
for construction of new nuclear facilities or in the retrofitting of existing
facilities. At this time, there are approximately 100 nuclear power plants in
the United States, of which approximately 40 are not currently in operation. Of
the operating nuclear power plants, approximately 50 are owned by the U.S.
Department of Energy ("DOE") and the balance are owned by public and private
utilities. There are also currently approximately 430 nuclear power plants in
the world which are not located in the United States or Russia. Because
accidents do occur at nuclear power plants for a variety of reasons, management
of the Company believes that a cost-effective safety shield system for new and
existing facilities is in great demand. To date, the Company has received a
purchase order for its material from the San Onofre Nuclear Generating Station
in San Onofre, California. That order is currently for 1,000 square feet of
material, to be provided in 100 square foot increments. The first shipment of
material, which will be used for in-house testing, was delivered in March 2000.
The Company also believes that its products can play an important role in
the recovery and reuse of materials from existing nuclear warheads. As nuclear
arsenals in the U.S. and former Soviet Union are dismantled, this application
will grow in importance.
In light of the huge and steadily growing deposits of worldwide nuclear
waste and related materials (447,000 metric tons according to 1995 estimates),
the properties of the Nurescell Technology are believed to have a worldwide
market as the means of correcting the existing problems with the handling and
storage of spent reactor fuel and various other radioactive materials, such as
uranium mill tailings and accelerator wastes.
Because of their special shielding needs, it is expected that nuclear
accelerator projects, as well as projects involving innovative fuels and defense
research applications, will find the Nurescell Technology useful in implementing
those projects. The same is expected to be true for X-ray rooms and linear
accelerators, where application of the Nurescell Technology as part of the room
shielding is made possible by the use of the spray-on version of the material.
In the U.S. alone, there are approximately 5,700 hospitals and 200,000
laboratories, all of which operate equipment which could use shielding provided
by the Nurescell Technology.
GOVERNMENTAL REGULATION. In the United States, the nuclear power industry
is highly regulated under the jurisdiction of the DOE and the Nuclear Regulatory
Commission ("NRC"), with the NRC having primary responsibility for enacting and
enforcing regulations designed to ensure the safety of nuclear power plants.
That regulatory authority extends from construction to all phases of operations.
In particular, the NRC has the authority to require nuclear power plants to
utilize specific measures to ensure and enhance their safety.
In the rest of the world, regulatory oversight of nuclear power plants is
effected through a Nuclear Safety Committee which is comprised of
representatives from throughout the world.
COMPETITION. The number of competitors offering proprietary products
designed to accomplish the same or similar effects as the Nurescell Technology
include Lockheed Martin, which utilizes the ceramic silicon foam technology, and
SAE (France), which utilizes a concrete-iron technology, among others. Other
companies may currently have or may succeed in developing products superior to
the Nurescell Technology, or may more effectively market such other products,
either of which could substantially reduce the potential market for products
using the Nurescell Technology.
Many of the Company's competitors are likely to enjoy substantial
competitive advantages, including the following:
- larger technical staffs;
- greater name recognition;
- larger customer bases; and
-3-
<PAGE>
- substantially greater financial, marketing, technical and other
resources.
If the Company does not compete effectively, or if it experiences any
pricing pressures, reduced margins or loss of market share resulting from
increased competition, its business will be adversely affected.
MARKETING STRATEGY. At this time, the Company plans to divide its major
market into the following divisions:
- medical applications, such as X-ray rooms;
- reactor spent nuclear fuel;
- Department of Defense special projects;
- environmental management and site restoration programs;
- "hot spots" and leaks in nuclear power stations and nuclear vessels;
- specialized advanced accelerator materials;
- high level nuclear wastes; and
- low level nuclear waste transportation.
The Company's marketing strategy is to develop its products in accordance
with the specifications and design which will be required by the NRC, DOE and
U.S. Department of Transportation and, in some situations, the Department of
Defense ("DOD"). The Company will then seek to present the Nurescell Technology
to the NRC, DOE and, as appropriate, the DOD, with emphasis on both the efficacy
of the technology and the cost savings which the technology will allow by
reducing downtime for maintenance. This presentation will be made with the
intent of having the NRC mandate that the Nurescell Technology be installed in
all nuclear power plants in the United States. The Company believes that if the
Nurescell Technology becomes the standard in the United States, it will also be
accepted as the standard worldwide.
At this time, it is expected that the Company's marketing organization
structure will be based upon the following:
- The use of technical personnel with substantial nuclear physics and
engineering, field technical sales and corporate product management
experience at the corporate level, each with a specific area of
technical expertise.
- Field Technical Sales Representatives with successful, in-depth
experience in nuclear physics and engineering and technical sales work
located in those geographical areas which will best serve the rapid
development of the Company's business.
- Presentations at nuclear power trade shows where independent
environmental engineering and consulting companies can be made
increasingly aware of the Nurescell Technology and the unique
applications that can serve their clients' needs.
As noted above, the Company is already providing its material to one
commercial domestic nuclear power plant and expects to obtain orders from other
domestic facilities within the next six months. In addition, if the Company is
able to move ahead as planned, it expects to begin involvement in a variety of
additional nuclear markets by the end of 2001, including international nuclear
plants, submarine-based nuclear reactors, DOD and DOE nuclear waste site
restoration projects and nuclear accelerator materials.
As part of its marketing strategy, the Company has entered into a five-year
consulting agreement with Dr. Chong Chiu, the former engineering and safety
manager of the San Onofre Nuclear Generating Station. Pursuant to that
agreement, Dr. Chiu is providing certain marketing, product development,
specification review and other services to the Company related to nuclear power
plants worldwide.
The Company is in the process of establishing an exclusive business
relationship with Lone Star Lead Construction ("Lone Star") regarding use of the
Nurescell Technology in the healthcare industry for applications such x-ray
rooms, linear
-4-
<PAGE>
accelerator rooms and radiation shielding doors. Lone Star is a division of The
Doe Run Company, the largest integrated lead company in the United States.
PRODUCT MANUFACTURING AND INSTALLATION. As of June 2000, the Company has
entered into a direct manufacturing relationship with Tek Tool Plastics
Company, Inc. for high-speed injection molding of the Nurescell material that
will increase production capability of the Company's solid material by
approximately ten times while reducing cost by a significant amount. The
Company does not anticipate any difficulty in obtaining the ingredients
needed to manufacture its products. For installation of its products, the
Company anticipates contracting with nuclear engineering firms to install
those products in nuclear power plants and other applications for the
encapsulation of nuclear materials.
INTELLECTUAL PROPERTY RIGHTS. At this time, a United States patent has
been applied for with respect to certain elements of the Nurescell
Technology. To date, no patents have been issued pending the results of
further legal work. It is anticipated that the ingredients of the Nurescell
Technology will also be manufactured under secrecy agreements. In addition,
the Company will pursue foreign patents and other U.S. and foreign protection
of its intellectual property to the extent appropriate under the
circumstances.
PERSONNEL. The Company currently has five employees (all of whom are
full-time) and three part-time consultants. It is anticipated that additional
employees will be hired as the need arises. It is also anticipated that the
Company will utilize third party contractors to handle various projects as
they arise.
PLAN OF OPERATION. The Company is a development stage company, with its
operations to date principally consisting of research, development and
testing of the Nurescell Technology. The Company is presently focused on
independent third party validation for the performance of its product, the
obtaining of patents for its technology, the establishment of manufacturing
procedures and processes, and the introduction of its product to the nuclear
industry. From inception to March 31, 2000, the Company has obtained
approximately $945,000 in financing through the sale of equity securities
through two private offerings (the "Offerings"), each of which has been
completed, approximately $95,000 through the exercise of stock options, and
another $396,500 through the issuance of convertible promissory notes (the
"Notes"). Through March 31, 2000, the Company utilized all of the proceeds of
the Offerings and option exercises and all of the net proceeds of the Notes
to (i) commence and pursue patent applications for the Nurescell Technology,
(ii) identify, negotiate and finalize suitable research, development and
testing contracts, (iii) identify, negotiate and finalize preliminary
marketing consulting contracts and (iv) provide working capital for the
ongoing administrative and financing acquisition costs of the Company. The
Company is presently funded for working capital by loans from Adrian Joseph
and another shareholder totaling $434,000 as of June 20, 2000. There is
currently an order to be filled providing for payment of approximately
$100,000 to the Company, shipment of which began in March 2000.
The Company's financial statements for the period ended March 31, 2000
have been prepared assuming that the Company will continue as a
going-concern. As noted in those financial statements, the presence of
significant losses, negative cash flows and limited working capital, together
with the uncertainties associated with the Company's ability to obtain
additional capital, raise substantial doubts as to its ability to continue as
a going-concern. See "Part F/S - Index to Financial Statements." The
Company's ability to continue as a going-concern will be questionable until
such time as it is able to generate sufficient revenues in excess of expenses
to sustain its normal business activities. Until that time, the Company will
depend on its ability to raise additional capital through either loans or
equity or debt offerings. At this time, the Company expects that it will need
approximately $3 million in additional financing over the next two years in
order to complete the necessary manufacturing capacity and marketing of the
Nurescell Technology. The Company currently anticipates financing of at least
$2 million to be derived from a "best efforts" private offering of equity
securities which is currently being discussed with several private investors.
There can, however, be no guarantee that such offering will be successfully
completed or that any additional funding will be available on terms favorable
to the Company or its shareholders, if at all. Without such funding, the
Company anticipates that its cash reserves, together with projected cash flow
from operations and loans, will be sufficient to fund its operations for no
more than the next four months. If sufficient funds are not available when
needed, the Company may be required to severely curtail its operations, which
would have a material adverse effect on the Company's business, operating
results and financial condition.
ITEM 7. DESCRIPTION OF PROPERTY.
The Company's executive office is located in leased premises of
approximately 2,200 square feet. The lease commenced on June 1, 1999 and
continues until May 31, 2002, with monthly rent of $3,679 which began on June 1,
1999
-5-
<PAGE>
(subject to annual base rent increases of 2.9% commencing June 1, 2000). The
Company expects that this space will be sufficient for its executive offices for
the foreseeable future.
ITEM 8. DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES.
Set forth below is information regarding the directors and executive
officers of the Company. The Company has no significant employees other than
those described below and there are currently no other persons under
consideration to become directors or executive officers of the Company.
<TABLE>
<CAPTION>
NAME AGE POSITION
---- --- --------
<S> <C> <C>
William A. Wilson 85 Chairman of the Board (a Director
position) and President
Adrian A. Joseph 47 Chief Executive Officer
Shelby T. Brewer 62 Director
John R. Longenecker 50 Director and Vice President - Operations
Sharon Nitka 38 Director, Chief Financial Officer and Secretary
Robert Merriman 58 Director
--
</TABLE>
WILLIAM A. WILSON has been the Chairman of the Board of the Company since
its inception on May 12, 1998 and its President since March 1, 2000. Mr. Wilson
has approximately fifty years of business experience in both the financial and
manufacturing fields and is currently an advisor and consultant to various high
technology and financial companies. Mr. Wilson is the former Chairman of the
Board of Web Wilson Oil Tools, Inc. and San Vicente Investments Co., and a
former member of the Boards of Directors of Jorgensen Steel Company, Penzoil
Company, Disease Detection International, Western Energy Management, Inc.,
Incomnet, Inc., National Registry Corporation, Orbit Technologies, Inc. and
several privately held companies. He is also a director and corporate Secretary
of Tresis International, a corporation in which Adrian A. Joseph is the majority
shareholder. Mr. Wilson was a delegate to several Republican conventions,
Chairman of the Presidential Personnel Selection Committee (Reagan
Administration), Presidential envoy to the Holy See (Vatican), first Ambassador
to the Holy See (Reagan Administration) and a trustee of President Reagan's
personal trust. Mr. Wilson holds a Bachelor of Science degree in Mechanical and
Metallurgical Engineering from Stanford University.
ADRIAN A. JOSEPH, PH.D. was the President of the Company from its inception
until August 1, 1999 and has served as Chief Executive Officer since August 1,
1999. Dr. Joseph holds a Ph.D. degree in nuclear physics from the Israel
Institute of Technology, which he earned in 1974. For 12 years prior to the
commencement of pre-organization work on the Company (which began in February
1996), Dr. Joseph was the founder and chief scientist and Chairman of the Board
of Orbit Technologies Inc., a publicly traded company engaged in developing
materials to treat existing hazardous waste. Dr. Joseph resigned his position
with Orbit Technologies Inc. in February 1996. Dr. Joseph has developed many
diverse technologies and holds 118 issued patents and has over 200 active patent
applications on file. Dr. Joseph's work has included metafusion (a process for
the fusion of metals at room temperature), low-cost titanium refining and
extraction, ultrasound technology for the reduction of viscosity in fluids, and
technologies in the coatings, plastics and foam areas. In 1994, he received an
Honors Award from the Euro-Asian Association of Physicists for High Achievement
in Nuclear Physics.
SHELBY T. BREWER, PH.D. has been a director of the Company since October
19, 1999. In 1996, Dr. Brewer founded S. Brewer Enterprises, Inc., of which he
is the President. S. Brewer Enterprises, Inc., which is based in Alexandria,
Virginia, provides consulting services to companies in the manufacturing,
engineering and financial services industries. From 1985 until 1996, Dr. Brewer
served in various executive positions with the Nuclear Business Unit of
Combustion Engineering, a division of Zurich-based ABB. From 1981 to 1984, Dr.
Brewer served as Assistant Secretary of Energy for the Reagan Administration.
Dr. Brewer holds B.A. and B.S. degrees from Columbia University and M.S. and
Ph.D. degrees from the Massachusetts Institute of Technology.
JOHN R. LONGENECKER has been a director and Vice-President of the
Company since its inception. Mr. Longenecker is also the President of
Longenecker & Associates, a management consulting firm with the high
technology and energy related businesses. Prior to the formation of
Longenecker & Associates in 1989, Mr. Longenecker was Chairman of General
Atomics International Services Corporation, a company which operates and
maintains nuclear power stations. From 1983 to 1987, Mr. Longenecker served
in the Reagan administration as the chief executive officer of the U.S.
uranium enrichment business in the DOE, and prior thereto worked in the
United States' nuclear reactor development program as the Director of Breeder
Demonstration Projects for the DOE. Mr. Longenecker received both his
Bachelor of Science and Master of Science degrees from Pennsylvania State
University and has served as a member of that institution's Industrial
Professional Advisory Council.
-6-
<PAGE>
SHARON NITKA has been a director and the Chief Financial Officer and
Secretary of the Company since its inception and is the sister of Adrian A.
Joseph. During the last five years, Ms. Nitka has also worked as a consultant
for Nagila Foods, Inc. ("Nagila"), a company which, among other things, operates
restaurants and prepares pre-packaged food items. Ms. Nitka's primary focus for
Nagila has been the development of an effective marketing strategy, including
community public relations. Other services for Nagila have included an in-depth
analysis of the operations management, which included creating a new branch of
delivery services and transforming Nagila's manual process to computerized
systems. Ms. Nitka has also held a variety of administrative and management
positions with various other companies. From 1985 to 1990, Ms. Nitka served as
the financial administrator of Orbit Technologies Inc. and a programmer analyst
with Metafuse Limited, both of which are or were controlled by Adrian A. Joseph.
Ms. Nitka holds a Bachelor degree in computer science and business.
ROBERT MERRIMAN, PH.D., has been a director of the Company since June 9,
2000. Since 1997, he has been President of Thunderhead Resources, LLC, a
private company he founded, which provides consulting services in the energy,
environmental and national security fields. From August 1994 to January 1997,
Dr. Merriman was the President and CEO of M4 Environmental, an Oak Ridge,
Tennessee, development stage company formed to develop and deploy innovative
radioactive, hazardous and mixed waste treatment technologies. In December
1997, M4 Environmental was included in the Chapter 11 bankruptcy filing of
its parent company, Molten Metal Technology, Inc. Prior to August 1994, he
held various senior executive management and technical positions with Martin
Marrietta Energy Systems and Union Carbide 's Nuclear Division. Dr. Merriman
holds a B.E. in Chemical Engineering from Vanderbilt University and M.S. and
Ph.D. degrees in Chemical Engineering from The University of Tennessee.
Subject to prior resignation or removal, the Company's directors serve
in that capacity until the next annual meeting of shareholders or until their
successors are elected or appointed and duly qualified. Officers are
appointed by the Board of Directors and serve in that capacity until
resignation or removal. Except as noted above, there are no family
relationships by blood, marriage or adoption among any directors and/or
executive officers of the Company, and there are no arrangements or
understandings between any director or executive officer and any other person
pursuant to which such director or executive officer was selected for his or
her office or position. Except as stated above, within the past five years
(i) no petition under the federal Bankruptcy Act or any state insolvency law
has been filed by or against any executive officer or director of the
Company, and no receiver, fiscal agent or similar officer has been appointed
by a court for the business or property of any such persons, or any
partnership in which any of such persons was a general partner at or within
the two years before the time of such filing, or any corporation or business
association of which any such person was an executive officer at or within
the past two years and (ii) no director or executive officer of the Company
has been convicted in a criminal proceeding (excluding traffic violations and
other minor offenses).
ITEM 9. REMUNERATION OF DIRECTORS AND OFFICERS.
COMPENSATION. The following table sets out the compensation paid on a cash
basis during the fiscal year ended March 31, 2000 to (i) each of the Company's
three highest paid officers or directors and (ii) the Company's officers and
directors as a group:
<TABLE>
<CAPTION>
NAME OR IDENTITY OF GROUP TITLE COMPENSATION(1)
------------------------- ----- ---------------
<S> <C> <C>
Adrian A. Joseph Chief Executive Officer $ 60,000(2)
Sharon Nitka Chief Financial Officer, Secretary & Director $ 23,080(3)
William A. Wilson President and Director $ 20,400(4)
All officers and directors as a group (7 persons) $ 240,080(5)(6)
</TABLE>
-----------------
(1) Does not include group life, health, hospitalization or other benefit plans
which do not discriminate in scope, terms or operation in favor of officers
or directors and which are available generally to all salaried employees.
(2) On January 3, 2000, Dr. Joseph was issued 500,000 shares of Common Stock as
a bonus award under Rule 16b- 3(d) of the Securities Exchange Act of 1934.
(3) On January 3, 2000, Ms. Nitka was issued 44,000 shares of Common Stock as a
bonus award under Rule 16b-3(d) of the Securities Exchange Act of 1934.
(4) On January 3, 2000, Mr. Wilson was issued 25,600 shares of Common Stock as
a bonus award under Rule 16b-3(d) of the Securities Exchange Act of 1934.
(5) On January 3, 2000, as a group, the Company's officers and directors were
issued a total of 704,032 shares of Common Stock as bonus awards under Rule
16b-3(d) of the Securities Exchange Act of 1934.
(6) Includes compensation to an officer who resigned on February 24, 2000 and a
director who resigned on March 11, 2000.
-7-
<PAGE>
STOCK OPTION PLAN. Under the Company's 1998 Stock Option Plan (the "Option
Plan"), all officers and directors of the Company, as well as its employees and
consultants, are eligible to be selected to participate. The purpose of the
Option Plan is to promote the interests of the Company by providing participants
with an inducement to maintain their status with the Company and to further
advance the interests of the Company. Options are granted in consideration of
things such as past and potential future contributions to the Company.
As of March 31, 2000, 360,000 options have been issued under the Option
Plan. The aggregate number of shares of Common Stock to be delivered upon the
exercise of all options granted under the Option Plan cannot exceed 360,000
shares. In the event of any merger, reorganization, recapitalization, stock
dividend, stock split or reverse split or other act or event which effects a
restructure of the Company's Common Stock (but not including the issuance of
additional shares of Common Stock or preferred stock), the total number of
shares covered by the Option Plan, the exercise price, and number of shares
covered by outstanding options granted pursuant to the Option Plan, and the
rights, preferences and privileges incident to such shares will be appropriately
adjusted as to any remaining options. Any shares covered by options granted
pursuant to the Option Plan which expire or are canceled are available for
reissuance under the Option Plan.
There is no maximum or minimum number of shares which may be subject to
options granted to any one individual under the Option Plan. The exercise price
of the stock covered by each option is determined at the time of grant;
provided, however, that (i) as to incentive stock options, such exercise price
will not be less than an amount equal to 100% of the "fair value" of the stock
(as determined pursuant to the Option Plan) on the date the option is granted
(110% for options granted to persons who hold 10% or more of the Company's
Common Stock) and (ii) as to all other options, such exercise price will not be
less than an amount equal to 85% of the fair value of the stock on the date the
option is granted. Subject to the express provisions of the Option Plan, the
terms of each option granted under the Option Plan, including the exercise
price, manner of exercise, vesting and duration of each option, shall be as
specified in the applicable option agreement between the Company and the option
holder.
The Board of Directors of the Company may amend, suspend or terminate the
Option Plan at any time. Unless terminated sooner, the Option Plan will
terminate on June 15, 2008 and no options may be granted thereafter. No
amendment, suspension or termination of the Option Plan will, without the
consent of the option holder, be made which would alter or impair any rights or
obligations under any option then outstanding. Upon the dissolution or
liquidation of the Company, the Option Plan will terminate, and any option
previously granted thereunder and not yet exercisable in full will also
terminate. In the event, however, that the Company is succeeded by another
corporation, the Option Plan and any remaining options granted thereunder will
be assumed by such successor corporation, subject to such adjustments as may be
necessary due to the capital structure of the successor corporation.
COMPENSATION ARRANGEMENTS. On May 15, 1998, the Company entered into a
three-year employment agreement with Adrian A. Joseph. The employment agreement
automatically renews for succeeding terms of one year, subject to the prior
notification of termination by either the Company or Dr. Joseph. Annual
compensation pursuant to the employment agreement is $240,000 per year, payable
monthly, subject to annual increases at the discretion of the Company's Board of
Directors. Dr. Joseph is also to receive an annual bonus equal to 10% of the
amount of annual Company profits which exceeds $300,000 over the Company's prior
year's profits. Although the employment agreement includes non-disclosure
covenants as to the Company's trade secrets, Dr. Joseph is permitted to pursue
other opportunities while serving as Chief Executive Officer of the Company, but
only with the consent of the Board of Directors.
On March 1, 2000, the Company entered into an employment agreement with
William A. Wilson, a Company director, by which he agreed to act as the
Company's President. Subject to earlier termination under certain
circumstances, the agreement terminates on August 31, 2000, with automatic
renewal for consecutive six-month terms unless either party gives notice to
the contrary. The agreement provides for a $144,000 per year base salary. In
addition, Mr. Wilson is to be issued 100,000 shares of Common Stock at the
end of each six month period of employment, and has been granted an option to
purchase up to 250,000 shares of Common Stock at $0.75 per share during a
specified period. In the event the agreement is terminated other than for
"cause," as defined in the agreement, or Mr. Wilson ends the agreement after
a "Change in Control" (also as defined in the agreement), he is to receive
his base salary and healthcare benefits for three months, extended to 12
months if he is terminated during a specified period surrounding a "Change
in Control."
The Company has also entered into an employment agreement with Sharon
Nitka. That agreement is terminable by the Company at any time, without cause,
and provides for an annual salary of $42,000 plus reimbursement of reasonable
expenses incurred in the furtherance of the Company's business.
The Company has entered into agreements with William A. Wilson, John R.
Longenecker, Shelby T. Brewer and Robert Merriman, each of whom is an officer
and/or director of the Company. Pursuant to those agreements (each of which
is terminable by either party on 30-days notice), the Company pays fees of
$2,000 per month to each of them for consulting services, plus reimbursement
of Company approved expenses (although Mr. Wilson receives no fees under his
agreement while the employment agreement described above remains in effect).
Except as noted above, the Company does not compensate its directors for
their services as such, although they have been granted options under the
Company's Option Plan. See "Stock Option Plan" above. It is, however, the policy
of the Company to reimburse directors for reasonable expenses incurred in
attending meetings of the Board of Directors.
-8-
<PAGE>
ITEM 10. SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS.
The following table sets forth the record ownership of the Company's Common
Stock (the Company's only class of voting stock) as of May 31, 2000 as to (i)
each person or entity who owns more than 10% of any class of the Company's
securities (including those shares subject to outstanding options), (ii) each
person named in the table appearing in "Item 9. Remuneration of Directors and
Officers" and (iii) all officers and directors of the Company as a group:
<TABLE>
<CAPTION>
NAME AND ADDRESS OF OWNER NUMBER OF SHARES OWNED(1) PERCENT OF CLASS (2)
------------------------- ------------------------- --------------------
<S> <C> <C>
Adrian A. and Dianna Joseph 6,721,750(3) 44.2%
1400 Bristol Street N., Suite 240
Newport Beach, California 92660
Sharon Nitka 383,260(3) 2.5%
1400 Bristol Street N., Suite 240
Newport Beach, California 92660
William A. Wilson 828,500(3) 5.5%
10101 Wilshire Boulevard
Los Angeles, California 90024
All officers and directors 8,775,110(3) 57.7%
as a group (5 persons)
</TABLE>
----------------------
(1) To the Company's knowledge, the persons named in the table have sole voting
and investment power with respect to all shares of Common Stock owned by
them, subject to community property laws where applicable.
(2) Based on 15,199,288 shares of Common Stock outstanding, without taking into
account any shares issuable upon the exercise of outstanding options or
warrants.
(3) Does not include shares which can be obtained pursuant to the exercise of
options or other stock acquisition rights described in the table below.
Other than the Class "A" Common Stock Purchase Warrants, the Company has no
class of non-voting securities presently outstanding.
The following table sets forth the options, warrants and other rights to
acquire securities of the Company which were held as of May 31, 2000 by (i)
each person or entity who owns more than 10% of any class of the Company's
securities, (ii) each person named in the table appearing in "Item 9.
Remuneration of Directors and Officers" and (iii) all officers and directors of
the Company as a group:
<TABLE>
<CAPTION>
TITLE AND AMOUNT
OF SECURITIES CALLED
FOR BY OPTIONS, EXPIRATION
NAME OF HOLDER WARRANTS OR RIGHTS(1) EXERCISE PRICE DATE
---------------- -------------------- -------------- ----------
<S> <C> <C> <C>
Adrian A. Joseph 100,000 shares of Common Stock $1.00/share Varies(2)
60,000 shares of Common Stock $0.55/share Varies(3)
Sharon Nitka 60,000 shares of Common Stock $0.50/share Varies(3)
William A. Wilson 250,000 shares of Common Stock $0.75/share (4)
100,000 shares of Common Stock (5) (5)
All officers and directors 820,000 shares of Common Stock $0.50 to Varies(2)(3)(4)(5)
as a group (5 persons) $2.00/share
</TABLE>
-------------
(1) All options in this table are fully vested.
(2) Options are exercisable only during the term of Dr. Joseph's employment
agreement, subject to extension to June 1, 2001 under certain
circumstances.
(3) Options are exercisable until July 31, 2003 as to Dr. Joseph, and until
July 31, 2008 as to the other optionees, subject in each case to earlier
termination in the event of death, disability and certain other events.
(4) Options are exercisable beginning on the date of employment and ending
on the earlier of the termination of employment or August 31, 2000.
(5) Pursuant to his employment agreement, Mr. Wilson is to be issued
100,000 shares of Common Stock at the end of each six month period of
employment.
-9-
<PAGE>
ITEM 11. INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS.
The following is a description of those transactions by the Company since
its inception or which are presently proposed in which (i) any Company director,
officer, promoter or greater than 10% shareholder (or a relative or spouse
thereof, or any relative of such spouse) has or is to have a direct or indirect
interest and (ii) the amount involved exceeds $50,000.
On June 12, 1998, the Company issued to Adrian A. Joseph (the Company's
Chief Executive Officer and majority shareholder) 10,000,000 shares of Common
Stock in return for his assignment of the Nurescell Technology which he
developed. At that time, the Company also paid Dr. Joseph approximately $34,000
for certain materials and supplies owned by him in connection with the
development of that technology.
The Company has also entered into employment agreements with Dr. Joseph,
William A. Wilson (the Company's President) and Sharon Nitka (the Company's
Chief Financial Officer and Secretary and a director), as described above in
"Item 9. Remuneration of Directors and Officers," and has granted stock
options to Dr. Joseph and Ms. Nitka, and stock options and periodic stock
acquisition rights to Mr. Wilson, as described in "Item 10. Security Ownership
of Management and Securityholders."
The Company has entered into agreements with William A. Wilson, John R.
Longenecker, Robert Merriman and Shelby T. Brewer (each of whom is an officer
and/or director), as described above in "Item 9. Remuneration of Directors
and Officers." Until her resignation as a director on March 11, 2000, Rita
Lavelle was a party to a similar agreement which provided for payments to her
of $4,000 per month.
From August 6, 1999 until his resignation on February 24, 2000, Harold L.
Rapp was employed pursuant to an employment agreement providing for an annual
base salary of $144,000 and 100,000 shares of Common Stock at the end of each
six month period of employment. In addition, Mr. Rapp was granted options to
purchase up to 250,000 shares of Common Stock at $0.75 per share (which have
since expired).
Dr. Joseph has made several unsecured loans to Nurescell totaling
approximately $257,000. Of those loans, approximately $79,000 is still
outstanding and is payable on demand with interest at 10% per year.
In December 1999, the Company issued 300,000 shares of Common Stock to
Shelby T. Brewer in connection with him becoming a Company director. In
addition, the Company granted to Mr. Brewer options to acquire up to 200,000
shares of Common Stock at $2.00 per share until October 31, 2000.
On January 3, 2000, the Company converted $698,968 of debt into 524,266
shares of Common Stock. Of those shares, 400,000 were issued to Adrian Joseph,
21,760 were issued to Sharon Nitka, 12,800 were issued to William A. Wilson,
12,800 were issued to John R. Longenecker, 32,016 were issued to Rita Lavelle (a
former director), 16,000 were issued to Harold Rapp (a former officer) and 6,400
were issued to Shelby T. Brewer.
Pursuant to its consulting agreement with Robert Merriman, the Company
is to issue him 300,000 shares of Common Stock. In addition, Dr. Merriman has
been granted options to purchase up to 200,000 shares of Common Stock at
$2.00 per share.
PART II
ITEM 1. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND
OTHER SHAREHOLDER MATTERS.
The Company's Common Stock is quoted on the OTC Bulletin Board under the
symbol "NUSL" and has been so quoted since June 22, 1999. Prior to that date,
there was no public trading market for the Company's equity securities. In
addition, the Company's Class "A" Common Stock Purchase Warrants (the "Class A
Warrants") are quoted on the OTC Bulletin Board under the symbol "NUSLW."
The following table sets forth the quarterly high and low bids for the
Company's Common Stock as reported by the OTC Bulletin Board since the beginning
of public trading:
-10-
<PAGE>
<TABLE>
<CAPTION>
COMMON STOCK
------------
FISCAL YEAR 2000 HIGH* LOW*
<S> <C> <C>
First quarter (starting June 22, 1999) ...... $5.50 $4.00
Second quarter .............................. $5.50 $1.4531
Third quarter ............................... $3.62 $1.25
Fourth quarter .............................. $4.375 $0.75
FISCAL YEAR 2001
First quarter (through June 15, 2000) ....... $3.375 $1.50
</TABLE>
---------
* These quotations reflect inter-dealer prices, without retail mark-up,
mark-down or commission, and may not represent actual transactions.
The Company has not paid any cash dividends on its Common Stock since its
incorporation and anticipates that, for the foreseeable future, any earnings
will be retained for use in its business. As of May 31, 2000, the number of
record holders of the Company's Common Stock was 294.
ITEM 2. LEGAL PROCEEDINGS.
Other than pending legal proceedings which have previously been reported in
the Company's reports on Form 10- QSB, to the knowledge of management, there is
no pending litigation by or against the Company.
ITEM 3. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS.
None, except as previously reported in the Company's reports on Form 8-K.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
There were no matters submitted to a vote of security holders during the
quarter ended March 31, 1999.
ITEM 5. COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.
During the fiscal year ended March 31, 2000, Form 3s were filed late by
William A. Wilson, Rita Lavelle, Harold L. Rapp, John R. Longenecker and Shelby
Brewer. In addition, the following Form 4s were filed late: (i) a May 1999 Form
4 by Adrian A. Joseph (reporting six transactions), (ii) a December 1999 Form 4
by William A. Wilson (reporting four transactions), (iii) an October 1999 and a
March 2000 Form 4 by John R. Longenecker (reporting two transactions) and (iv)
an October 1999 Form 4 and January and February 2000 Form 4s by Rita Lavelle
(reporting a total of eight transactions).
ITEM 6. REPORTS ON FORM 8-K.
The Company filed one report on Form 8-K during the quarter ended March 31,
2000. Such report is dated January 24, 2000 and provided disclosure under Item 4
regarding changes in the Company's certifying accountant. No financial
statements were required to be filed with such report.
On January 28, 2000, the Company filed an amendment to its report on Form
8-K dated December 16, 1999. Such amendment provided disclosure under Item 4
regarding changes in the Company's certifying accountant. No financial
statements were required to be filed with such amendment.
-11-
<PAGE>
NURESCELL INC.
INDEX TO FINANCIAL STATEMENTS
Report of Independent Auditors for the year ended March 31, 2000 F-1
Report of Independent Auditors for the period ended March 31, 1999 F-2
Balance Sheets as of March 31, 2000 and 1999 F-3
Statements of Operations for the year ended March 31, 2000, for the
period May 12, 1998 (Date of Inception) to March 31, 1999 and
cumulative for the period May 12, 1998 (Date of Inception) to
March 31, 2000 F-4
Statements of Shareholders' Equity (Deficiency) for the period
May 12, 1998 (Date of Inception) to March 31, 2000 F-5
Statements of Cash Flows for the year ended March 31, 2000, for the
period May 12, 1998 (Date of Inception) to March 31, 1999 and
cumulative for the period May 12, 1998 (Date of Inception) to
March 31, 2000 F-6
Notes to Financial Statements F-7
<PAGE>
REPORT OF INDEPENDENT AUDITORS
To the Board of Directors and Shareholders of
Nurescell Inc.
We have audited the accompanying balance sheet of Nurescell Inc. (A Company in
the Development Stage) as of March 31, 2000 and the related statement of
operations, shareholders' deficiency, and cash flows for the year then ended and
the cumulative from the period April 1, 1999 through March 31, 2000. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatements. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Nurescell Inc. (A Company in
the Development Stage) as of March 31, 2000, and the results of its operations
and its cash flows for the year then ended and the cumulative from the period
April 1, 1999 through March 31, 2000 in conformity with generally accepted
accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 1 to the
financial statements, there is substantial doubt about the ability of the
Company to continue as a going concern. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.
HOLLANDER, LUMER & CO. LLP
Los Angeles, California
June 22, 2000
F-1
<PAGE>
REPORT OF INDEPENDENT AUDITOR
RONALD L. JAMIESON, CPA
Certified Public Accountants
4281 Katella Ave. Suite 117, Los Alamitos, CA 90720
(714) 821-9690 * (562) 598-8549 * Fax (714)821-9286
June 15, 1999 except for Note 12 dated June 22, 2000
To the Board of Directors
Nurescell Inc.
Irvine, CA 92614
I have audited the accompanying balance sheet of Nurescell Inc. (a development
stage company) as of March 31, 1999 and the related statement of operations,
stockholders' equity (deficiency), and cash flows for the period from May 12,
1998 (inception) to March 31, 1999. These financial statements are the
responsibility of the Company's management. My responsibility is to express an
opinion on these financial statements based on my audits.
I conducted my audit in accordance with generally accepted auditing standards.
Those standards require that I plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatements. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
I believe that my audits provide a reasonable basis for my opinion.
In my opinion, the financial statements referred to above present fairly, in all
material respects, the balance sheet of Nurescell Inc. as of March 31, 1999,
and the results of its operations and its cash flows for the period from May 12,
1998 (inception) to March 31, 1999, in conformity with generally accepted
accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company is a development stage
enterprise engaged in developing certain radiation shielding technology. As
discussed in Note 1 to the financial statements, the Company's accumulated
losses from operations and negative operating cash flows; its necessity to
obtain additional financing to fund operations until the necessary regulatory
approvals are obtained, if ever; and its ability to ultimately attain successful
operations raise substantial doubt about its ability to continue as a going
concern. Management's plans concerning these matters are described in Note 1.
The financial statements do not include any adjustments that might result from
the outcome of this uncertainty.
Ronald L. Jamieson, CPA
F-2
<PAGE>
NURESCELL INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
BALANCE SHEETS
MARCH 31, 2000 AND 1999
<TABLE>
<CAPTION>
2000 1999
------------ ------------
ASSETS
<S> <C> <C>
CURRENT ASSETS
Cash $ 26,945 $ 125,421
Stock subscriptions receivable -- 25,000
Accounts receivables 8,700 --
Inventory 25,078 --
Advance to employees -- 12,075
Due from officer -- 54,673
Other receivable -- 3,761
Other prepaid expenses 13,732 --
------------ ------------
TOTAL CURRENT ASSETS 74,455 220,930
------------ ------------
PROPERTY AND EQUIPMENT net of accumulated
Depreciation and amortization of $14,021 and $5,881 48,937 43,100
OTHER ASSETS
Prepaid financing cost 84,999 --
Deposits 3,679 3,000
Intangibles 30,005 8,609
Unamortized discount on notes payable 236,310 --
------------ ------------
TOTAL OTHER ASSETS 354,993 11,609
------------ ------------
TOTAL $ 478,385 $ 275,639
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)
CURRENT LIABILITIES
Accounts payable $ 139,289 $ 34,826
Due to officer 79,367 --
Accrued expenses 120,092 9,839
------------ ------------
TOTAL CURRENT LIABILITIES 338,748 44,665
NOTES PAYABLE 770,000 --
------------ ------------
TOTAL LIABILITIES 1,108,748 44,665
SHAREHOLDERS' EQUITY (DEFICIENCY)
Preferred stock, $.001 par value; authorized - 1,000,000 shares;
issued and outstanding - none -- --
Common stock, $.0001 par value; authorized - 50,000,000 shares;
issued and outstanding - 15,191,788 shares in 2000 and
13,082,000 shares in 1999 1,519 1,308
Additional paid-in capital 4,028,739 904,192
Accumulated deficit (4,660,621) (674,526)
------------ ------------
TOTAL SHAREHOLDERS' EQUITY (DEFICIENCY) (630,363) 230,974
------------ ------------
TOTAL $ 478,385 $ 275,639
============ ============
</TABLE>
See accompanying Notes to Financial Statements
F-3
<PAGE>
NURESCELL INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF OPERATIONS
<TABLE>
<CAPTION>
Cumulative
For the period For the period
For the year May 12, 1998 May 12, 1998
ended (Date of Inception) (Date of Inception)
March 31, 2000 to March 31, 1999 to March 31, 2000
--------------- ------------------ ------------------
<S> <C> <C> <C>
SALES $ 8,700 $ -- $ 8,700
COST OF SALES 21,377 -- 21,377
-------------- ---------------- --------------
GROSS LOSS (12,677) -- (12,677)
OPERATING EXPENSES
Research and development 64,632 2,000 66,632
General and administrative 3,879,937 670,039 4,549,976
Depreciation 9,362 5,881 15,243
-------------- ---------------- --------------
TOTAL EXPENSES 3,953,931 677,920 4,631,851
-------------- ---------------- --------------
LOSS FROM OPERATIONS (3,966,608) (677,920) (4,644,528)
OTHER INCOME (EXPENSE)
Interest income (expense) (12,709) 3,394 (9,315)
Loss on abandonment of computer software (6,778) -- (6,778)
-------------- ---------------- --------------
TOTAL OTHER INCOME (EXPENSE) (19,487) 3,394 (16,093)
-------------- ---------------- --------------
NET LOSS $ (3,986,095) $ (674,526) $ (4,660,621)
============== ================ ==============
BASIC AND DILUTED LOSS PER SHARE $ (0.29) $ (0.06) $ (0.36)
============== ================ ==============
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING 13,610,906 12,086,916 13,003,247
============== ================ ==============
</TABLE>
See accompanying Notes to Financial Statements
F-4
<PAGE>
NURESCELL INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIENCY)
FOR THE PERIOD FROM MAY 12, 1998 (INCEPTION DATE) TO MARCH 31, 2000
<TABLE>
<CAPTION>
COMMON STOCK ADDITIONAL
-------------------------- PAID IN ACCUMULATED
SHARES AMOUNT CAPITAL DEFICIT TOTAL
-------------------------- ----------- ------------ -----------
<S> <C> <C> <C> <C> <C>
Issuance of common stock
Cash - Founding Shareholders (March 1998 at $.001) 2,100,000 $ 210 $ 1,890 $ -- $ 2,100
Cash - Founding Shareholders (June 1998 at $.001) 400,000 40 360 400
Purchase of Technology (June 1998 at $.0001) 10,000,000 1,000 (1,000) --
Cash - $1.00 per share (August 1998) 498,000 50 497,950 498,000
Cash - $5.00 per share, net of issuance cost
(September 1998) 19,800 2 87,720 87,722
Cash - $5.00 per share, net of issuance cost
(October 1998) 5,200 1 23,038 23,039
Cash - $5.00 per share, net of issuance cost
(November 1998) 1,500 6,645 6,645
Cash - $5.00 per share, net of issuance cost
(February 1999) 12,000 1 53,163 53,164
Cash - $5.00 per share, net of issuance cost
(March 1999) 40,500 4 179,426 179,430
Common stock subscriptions 5,000 25,000 25,000
Fair value of options 30,000 30,000
Net loss, as restated for March 31, 1999 (674,526)
---------- ----------- ----------- ------------ -----------
BALANCE, MARCH 31, 1999 13,082,000 1,308 904,192 (674,526) 230,974
Issuance of common stock
Cash $100 and investment bankings services
(May 1999 at $2.50) 30,000 3 74,997 75,000
Consulting services (October 1999 at $1.17) 8,000 1 9,359 9,360
Consulting services (December 1999 at $1.10) 134,000 13 147,597 147,610
Consulting services (January 2000 at $.98) 100,000 10 98,240 98,250
Exercise of stock options (October 1999 at $.50) 60,000 6 29,994 30,000
Exercise of stock options (October 1999 at $.50) 60,000 6 29,994 30,000
Exercise of stock options (January 2000 at $1.00) 15,000 2 14,999 15,001
Exercise of stock options (March 2000 at $2.00) 10,000 1 19,999 20,000
To a director (December 1999 at $1.78) 300,000 30 533,970 534,000
To employees (December 1999 at $2.25) 20,000 2 44,998 45,000
To employee (December 1999 at $1.88) 100,000 10 187,490 187,490
Conversion of debt to capital
(January 2000 at $1.17) 524,226 52 614,275 614,327
Award to directors and officers
(January 2000 at $1.17) 734,562 73 860,742 860,815
Cash (April 1999 at $5.00) 14,000 2 69,998 70,000
Fair value of options and warrants 387,895 387,895
Net loss (3,986,095) (3,986,095)
---------- ----------- ----------- ------------ -----------
BALANCE, MARCH 31, 2000 15,191,788 $ 1,519 $ 4,028,739 $(4,660,621) $ (630,363)
========== =========== =========== ============ ===========
</TABLE>
See accompanying Notes to Financial Statements
F-5
<PAGE>
NURESCELL INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF CASH FLOWS
<TABLE>
<CAPTION>
Cumulative
For the period For the period
May 12, 1998 May 12, 1998
For the year (Date of (Date of
ended Inception) to Inception) to
March 31, 2000 March 31, 1999 March 31, 2000
-------------- -------------- --------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss $(3,986,095) $ (674,526) $(4,660,621)
Adjustments:
Depreciation 9,362 5,881 15,243
Amortization of discount on notes payable 33,690 -- 33,690
Loss on abandonment of computer software 6,778 -- 6,778
Issuance of stock for services 1,957,435 -- 1,957,435
Issuance of stock for conversion of debt to capital 614,327 -- 614,327
Fair value of options and warrants 387,895 30,000 417,895
Changes in operating assets and liabilities
Accounts receivable (8,700) -- (8,700)
Inventory (25,078) -- (25,078)
Prepaid financing cost (84,999) -- (84,999)
Other prepaid expenses (13,732) -- (13,732)
Advances to employee 12,075 (12,075) --
Due from officer 54,673 (54,673) --
Other receivables 3,761 (3,761) --
Due to officers 79,367 -- 79,367
Accounts payable 104,463 34,826 139,289
Accrued salaries and payroll taxes payable 87,054 9,839 96,893
Other accrued expenses 23,199 -- 23,199
-------------- -------------- --------------
Net Cash Flows Used by Operating Activities (744,525) (664,489) (1,409,014)
-------------- -------------- --------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment (21,977) (48,981) (70,958)
Deposits (679) (3,000) (3,679)
Intangibles (21,396) (8,609) (30,005)
-------------- -------------- --------------
Net Cash Flows Used by Investing Activities (44,052) (60,590) (104,642)
-------------- -------------- --------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock 190,101 850,500 1,040,601
Proceeds from issuance of convertible notes 500,000 -- 500,000
-------------- -------------- --------------
Net Cash Flows Provided by Financing Activities 690,101 850,500 1,540,601
-------------- -------------- --------------
Net increase (decrease) in cash (98,476) 125,421 26,945
Cash at beginning of year 125,421 -- --
-------------- -------------- --------------
Cash at end of year $ 26,945 $ 125,421 $ 26,945
============== ============== ==============
SUPPLEMENTAL DISCLOSURES OF NON-CASH
FINANCING ACTIVITIES
Issuance common stock for services $ 1,957,435 $ -- $ 1,957,435
Issuance of common stock for conversion of debt to equity 614,327 -- 614,327
-------------- -------------- --------------
Fair value of options and warrants to non-employees 387,895 30,000 417,895
-------------- -------------- --------------
$ 2,959,657 $ 30,000 $ 2,989,657
============== ============== ==============
</TABLE>
See accompanying Notes to Financial Statements
F-6
<PAGE>
NURESCELL INC.
(A Company in the Development Stage)
NOTES TO FINANCIAL STATEMENTS
1. GENERAL
DESCRIPTION OF BUSINESS: Nurescell Inc. (the "Company") was incorporated in
Nevada on May 12, 1998 for the purpose of developing and commercially
exploiting a proprietary radiation shielding technology (the "Nurescell
Technology") for use by the nuclear power industry and others producing,
handling or storing radioactive materials. The Nurescell Technology material,
which is comprised of a unique composite of materials, is designed for
incorporation into the structural components of new and existing nuclear
reactors and other facilities in order to provide a cost-effective safeguard
from the lethal effect of radiation while achieving a minimal disruption to
existing facilities. It is also being designed as a containment material
which will provide an attractive alternative to the conventional technologies
currently used to transport and store ever-increasing amounts of spent
nuclear fuel and other radioactive waste. In addition, it is expected to
provide an innovative shielding material for various other purposes,
including nuclear accelerator and defense research applications. The Nurescell
Technology is based upon a proprietary formulation which was acquired from
Adrian A. Joseph, Ph.D. the Company's Chief Executive Officer and majority
shareholder, in June 1998.
The Company's Common Stock is quoted on the OTC Bulletin Board under the symbol
"NUSL", and has been so quoted since June 10, 1999. Prior to that date, there
was no public trading market for the Company's equity securities. In addition,
the Company's Class "A" Common Stock Purchase Warrants (the "Class A Warrants")
are quoted on the OTC Bulletin Board under the symbol "NUSLW".
The Company is in its pre-production and testing stage, and therefore, it
currently has only limited sales, and is not extensively marketing the Nurescell
Technology.
GOING CONCERN: The Company has accumulated net losses of $4,660,621 and
negative working capital of $264,293 as of March 31, 2000. The Company's
capacity to operate as a going-concern is dependent on its ability to obtain
adequate financing to fund its operations until the Company is able to
complete the necessary testing required to generate commercial revenues
sufficient to fund ongoing operations. At this time, the Company expects that
it will need approximately $3 million in additional financing over the next
two years in order to complete the necessary manufacturing capacity and
marketing of the Nurescell Technology. The Company currently anticipates
financing of at least $2 million to be derived from a "best efforts"
private offering of equity securities which is currently being discussed with
several private investors. There can, however, be no guarantee that such
offering will be successfully completed or that any additional funding will be
available on terms favorable to the Company or its shareholders, if at all.
These factors, among others, raise substantial doubt about the Company's
ability to continue as a going concern. The financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
BASIS OF PRESENTATION: Since the Company has limited revenues and has not yet
commenced its principal operations, it is considered a "development stage
enterprise," as defined by Statement of Financial Accounting Standards ("SFAS)
No. 7, Accounting and Reporting by Development Stage Enterprises.
F-7
<PAGE>
FISCAL YEAR: The Company adopted a fiscal year ending March 31. These financial
statements include the transactions from the inception of the Company, May 12,
1998 to March 31, 2000.
START-UP ACTIVITIES: In 1998, the American Institute of Certified Public
Accountants ("AICPA") amended the AICPA Statement of Position ("SOP") and Audit
and Accounting Guides addressing the reporting of costs of start-up activities.
Effective for fiscal years beginning after December 15, 1998, SOP 98-5 requires
costs of start-up activities and organizational costs to be expenses as
incurred. Because early application is encouraged in prior periods, the Company
has restated the financial statements to conform.
USE OF ESTIMATES: The preparation of financial statements in conformity with
generally accepted accounting principles requires management, to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS: The Company considers all highly liquid investments
purchased with an original maturity of three months or less to be cash
equivalents.
EARNINGS PER SHARE: Basic Earnings per Share ("EPS") is calculated by dividing
income available to common stockholders (the "numerator") by the weighted
average number of common shares outstanding (the "denominator") during the
period. The computation of diluted EPS is similar to the computation of basic
EPS except that the denominator is increased to include the number of additional
common shares that would have been outstanding if the dilutive potential common
shares (that is, securities such as options, warrants, convertible securities,
or contingent stock agreements) had been issued. In addition, in computing the
dilutive effect of convertible securities, the numerator is adjusted to add back
(a) any convertible preferred dividends and (b) the after-tax amount of interest
recognized in the period associated with any convertible debt. The computation
of diluted EPS does not assume conversion, exercise, or contingent issuance of
securities that would have an antidilutive effect on EPS.
INCOME TAXES: The Company utilizes the asset and liability method for income
taxes. Under this method, deferred tax assets and liabilities are recognized for
the future tax consequences attributable to differences between the financial
statement carrying amounts of existing assets and liabilities and their
respective tax bases and operating loss and tax credit carryforwards. Deferred
tax assets and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary differences are
expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that
includes the enactment date.
RESEARCH AND DEVELOPMENT COSTS: Research and development costs are expensed as
incurred.
F-8
<PAGE>
PROPERTY AND EQUIPMENT: Property and equipment are stated at cost. Depreciation
is provided using the straight-line method over the estimated useful lives of
the assets. Useful lives generally are as follows:
Furniture and fixtures 7 years
Computers 5 years
Tooling and molds 7 years
Equipment 7 years
INVENTORIES: Inventories have been valued at the lower of cost (weighted
average) or market.
STOCK-BASED COMPENSATION: Statement of Financial Accounting Standards No. 123,
"Accounting for Stock-Based Compensation" ("SFAS No. 123"), encourages, but does
not require a fair value based method of accounting for stock options. The
Company elected to continue to account for stock-based compensation using the
intrinsic value method prescribed in Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB No. 25"), and related
interpretations, under which no compensation cost related to stock options has
been recognized as the exercise price of each option at the date of grant was
equal to the fair value of the underlying common stock.
OTHER ASSETS: Other assets consist of deposits, intangibles, and unamortized
discount on notes payable (See Note 7). Intangibles include patent application
and associated legal costs. Upon commencement of operations, all costs
associated with obtaining patents will be amortized on a straight-line basis
over a 17-year period. The Company will evaluate the recoverability of
intangibles on an annual basis by comparing the estimated net realizable value
of the intangibles to their carrying value.
3. INTANGIBLE ASSETS
In June 1998, the Company entered into a Sale of Technology Agreement
("Agreement") with Dr. Adrian Joseph (now an officer of the Company) whereby
the Company acquired all rights, title and interest in a new generation of
flexible containment material ("Nuresfoam") for radioactive material
("Technology"). The Technology is based, in part, on prior patented
technology, however the Technology itself has not yet been patented nor
trademarked.
As consideration for the sale of the Technology, Dr. Joseph received 10,000,000
shares or 80% of the Company's then outstanding Common Stock. The transfer of
the Technology was intended to be a tax-free exchange in accordance with
Internal Revenue Code Section 351. The Agreement stated that the Company valued
the Technology at $5,000,000; however, Staff Accounting Bulletin No. 48 stated
that "transfers of nonmonetary assets to a company by its shareholders in
exchange for stock prior to or at the time of the company's initial public
offering normally should be recorded as the transferor's historical cost basis
determined under generally accepted accounting principles". Consequently, the
Technology has been recorded at a zero basis.
F-9
<PAGE>
4. PROPERTY AND EQUIPMENT
Property and equipment is consisted of the following at March 31, 2000 and 1999:
<TABLE>
<CAPTION>
2000 1999
-------------- ---------------
<S> <C> <C>
Furniture and fixtures $ 6,070 $ 836
Computers 25,055 29,847
Tooling and molds 12,140 -
Equipment 19,693 18,298
-------------- ---------------
62,958 48,981
Less: accumulated depreciation 14,021 5,881
-------------- ---------------
$ 48,937 $ 43,100
============== ===============
</TABLE>
5. INVENTORIES
Inventories consisted of the following at March 31, 2000:
Raw material $ 18,378
Work in process
2,100
Finished goods
4,600
==============
$ 25,078
==============
6. DUE TO OFFICER
Due to officer at March 31, 2000 consisted of short-term cash advance from Dr.
Adrian Joseph, the Chief Executive Officer, payable on demand, and bearing
interest at 10% per annum.
7. CONVERTIBLE NOTES PAYABLE
On December 15, 1999 and February 8, 2000, respectively, the Company signed
convertible promissory notes to Triton Private Equities Fund, L.P. ("Triton"),
each with a face value $385,000 and bearing interest at 8% per annum ("December
note" and "February note"). Interest for the December and February notes are due
quarterly beginning March 31, 2000 and June 30, 2000, respectively. For both
notes, the Company recorded an original issue discount of $270,000, legal fees
in the amount of $28,500, and finders' fee in the amount of $50,000.
Additionally, a refundable prepaid fee of $25,000 was withheld by Triton to
reserve an equity credit line, which the Company has decided not to pursue. As
of March 31, 1999, Triton still held the $25,000.
The December note has a warrant feature for 25,000 shares of Company Common
Stock, with a three-year expiration date. The February note has a warrant
feature for 75,000 shares of the Company Common Stock, also with a three-year
expiration date. Accounting Principles Board Opinion No. 16 requires that
separate amounts attributable to the debt and the purchase warrant
F-10
<PAGE>
be computed and accounting recognition be given to each component. The warrants
were valued at fair value at the grant date using the Black-Scholes pricing
model. The warrants of December and February notes can be converted into Common
Stock for $ 2.25 and $4 per share, respectively.
The discount and other expenses related to the issuance of convertible
promissory notes are being amortized over the two-year life of the December note
and over the 22-month life of the February note.
Interest on the notes can be paid in shares of the Company's Common Stock at the
discretion of the Company, as follows: the dollar amount of the interest to be
paid divided by the average of the closing bid prices for the Common Stock for
the ten (10) trading days prior to the due date of such interest payment
multiplied by ninety percent (90).
The holder of the convertible promissory note can convert it to the Company's
Common Stock at its option, any time commencing the earlier of (i) the date
on which the Registration Statement is declared effective by the SEC; or (ii)
the date which is one hundred twenty days after the date of the note. The
holder is entitled to convert all or a portion of the original principal face
amount of this note into shares of common stock at a conversion price for
each share of common stock equal to the lesser of (a) one hundred twenty-five
percent (125%) of the closing price of the Company's Common Stock at the date
of the note or (b) the average of the three lowest bid prices of the
Company's Common Stock for twenty (20) trading days prior to the conversion
date - at a price per share per the following sliding formula:
date of note to 120 days = 105%
121 days to 150 days = 103%
151 days to 180 days = 100%
181 days to 210 days = 97%
more than 210 days = 95%
8. SHAREHOLDERS' EQUITY
In March and June of 1998, the Company issued 2,100,000 and 400,000 shares,
respectively, of the Company's Common Stock to the founding shareholders of the
Company at $.001 per share.
In June 1998, the Company issued 10,000,000 shares of the Company's Common Stock
to Adrian Joseph as consideration for the sale of his technology to the Company.
In August 1998, the Company received net proceeds of $498,000 in a private
placement of 498,000 shares the Company's Common Stock at $1 per share.
During September 1998 through March 1999, the Company received net proceeds of
$350,000 in several private placements totaling 79,000 shares of the Company's
Common Stock at $5 per share.
F-11
<PAGE>
In May 1998, the Company, pursuant to the employment agreement, granted Adrian
Joseph, the Chief Executive Officer of the Company, an option to purchase
100,000 shares of the Company's Common Stock at $1.00 per share. The options
were valued at $1 per share.
In June 1998, the Board of Directors approved a Non-qualified Stock Option
Plan granting to any director, officer, employee or consultant to the Company
options to purchase the Company's Common Stock over a ten-year period, at the
fair market value at time of grant. The aggregate number of common shares of
the Company which may be granted under the plan is 360,000 shares (300,000
shares at $.50 per share and 60,000 shares to Dr. Adrian Joseph at $.55 per
share). As of March 31, 2000, options for 360,000 shares have been granted
under the plan. In October 1999, Eric Michelman, a consultant to the Company,
exercised his option for 60,000 shares. In October 1999, William Wilson, a
member of the board of the Company, exercised his option for 60,000 shares.
In August 1998, the Company granted Douglas Denhart, a finder, an option to
purchase 24,000 shares of the Company's Common Stock at $1.00 per share for his
past services to the Company. These options were valued at $2.50 per share.
In March 1999, the Company received subscriptions for 5,000 shares of the
Company's Common Stock at $5 per share. Subsequently, in April 1999, the
monies were received and the stocks were issued.
In April 1999, the Company granted Robert Shaw, a consultant to the Company, an
option to purchase 15,000 shares of the Company's Common Stock at $1.00 per
share for each month that he provides services under his agreement with the
Company. The options were valued at various prices. As of March 31, 2000, he was
granted a total of 180,000 options, of which, 15,000 shares were exercised in
January 2000.
In May 1999, the Company granted Robert Cannone, a finder, an option to purchase
11,000 shares of the Company's Common Stock at $1.00 per share for his past
services to the Company. These options were valued at $2.50 per share.
In July 1999, the Company issued to National Capital Merchant Group, Ltd. 30,000
shares of the Company's Common Stock valued at $2.50 per share for past
investment banking services to the Company.
In September 1999, the Company issued to James Barone, a finder, 8,000 shares of
the Company's Common Stock valued at $1.17 per share for his past services to
the Company.
In December 1999, pursuant to a consulting agreement, the Company issued
134,000 shares of Company's Common Stock to Dr. Chiu. These shares were valued
at $2.20 per share.
In December 1999, the Company issued to Shelby Brewer, a member of the board of
the Company, 300,000 shares of Company's Common Stock valued at $1.78 per share
pursuant to the terms of his consulting agreement with the Company. Also under
the agreement, Mr. Brewer has been granted an option to purchase 200,000 shares
of the Company's Common Stock for $2 per share any time between November 1, 1999
and October 31, 2000. (See Note 11) In March 2000, Mr. Brewer exercised his
option for 10,000 shares.
F-12
<PAGE>
In December 1999, the Company issued to Kay Barone and Jasmine Kastor, both
employees of the Company, 10,000 shares each of the Company's Common Stock
valued at $2.25 per share for their past services to the Company. Additionally,
Ms. Barone and Ms. Kastor were granted options to purchase 10,000 shares each of
the Company's Common Stock for $2.20 per share. As of March 31, 2000, these
options have not been exercised.
In December 1999, the Company issued to Harold Rapp, a former President of the
Company, 100,000 shares of the Company's Common Stock valued at $1.88 per share.
In January 2000, the Company issued to Dutchess Advisors, Ltd. 100,000 shares of
the Company's Common Stock valued at $.98 per share for past consulting services
to the Company.
The Company applies Accounting Principles Board Opinion No. 25, Accounting
for Stock Issued to Employees and related interpretations in accounting for
its stock options. Accordingly, no compensation expense has been recognized
for the options granted under the Non-Qualified Stock Option Plan.
Compensation cost is based upon the fair value at the grant date consistent
with the methodology prescribed under SFAS No. 123, "Accounting for
Stock-Based Compensation". The Company's net loss and loss per share would
have been increased by approximately $444,058 or $.03 per share for March 31,
2000 and $25,750 for 1999, respectively, had compensation expense been
recognized. The fair value of the options granted during fiscal year ended
March 31, 2000, is estimated to range from $1.73 to $2.19 on the date of
grant using the Black-Scholes option-pricing model with the following
assumptions: dividend yield of 0%, volatility of 2,521%, risk free interest
rate of 5.5%, and an expected life of 3-10 years.
The following non-qualified stock options granted by the Company were
outstanding at March 31, 2000:
<TABLE>
<CAPTION>
Exercise
Number of Price per
Shares Share Date of Grant Date of Vesting Date of Expiration
------------------ ----------------- -------------------------- ------------------------- ----------------------
<S> <C> <C> <C> <C>
100,000 $ 1.00 July 15, 1998 July 15, 1998 June 1, 2001
60,000 0.55 July 31, 1998 July 31, 1998 June 15, 2006
180,000 0.50 July 31, 1998 July 31, 1998 June 15, 2008
24,000 1.00 August 13, 1998 August 13, 1998 none
165,000 1.00 April 1, 1999 Various none
11,000 1.00 May 7, 1999 May 7, 1999 May 7, 2002
20,000 2.20 November 5, 1999 November 5, 1999 none
190,000 2.00 November 1, 1999 November 1, 1999 none
250,000 0.75 March 1, 2000 March 1, 2001 none
------------------
1,000,000
==================
</TABLE>
In September 1998, the Board of Directors approved an offering of units
consisting of one share of Common Stock (the "Common Stock") and one Class "A"
Common Stock Purchase Warrant (the "Class A Warrants") of the Company.
F-13
<PAGE>
The Class "A" Warrants are exercisable into one share of Common Stock and one
Class "B" Common Stock Purchase Warrant (the "Class "B" Warrant") commencing
the day immediately after the first anniversary of the closing of the
offering (the "A Exercise Date") and have an exercise price of $4.00. The
Class "A" Warrants expire on the first anniversary of the "A Exercise Date"
(the "A Expiration Date"). The Class "B" Warrants are exercisable into one
share of Common Stock commencing immediately upon their issuance (the "B
Exercise Date") and have an exercise price of $3.00 per share of Company
Common Stock. The Class "B" Warrants expire on the first anniversary of the
"B Exercise Date."
Prior to permitting the exercise of either the Class "A" or Class "B"
Warrants, the Company was required to either register the underlying
Common Stock or seek an exemption from registration under both federal and
state law. The Common Stock and the Class A warrants are immediately
detachable.
The following warrants granted by the Company were outstanding at March 31,
2000:
<TABLE>
<CAPTION>
Exercise
Number of Price per
Shares Share Date of Grant Date of Vesting Date of Expiration
----------------- -------------- ---------------------------- ------------------------- -------------------------
<S> <C> <C> <C> <C>
98,000 $ 4.00 March 31, 1999 November 10, 1999 November 9, 2000
25,000 2.25 December 15, 1999 December 15, 1999 December 14, 2002
75,000 4.00 February 8, 2000 February 8, 2000 February 7, 2003
=================
198,000
=================
</TABLE>
The warrants/options granted to non-employees during fiscal year ended March 31,
1999 and 2000 were valued using the fair value at the grant date consistent with
the methodology prescribed under SFAS No. 123. Compensation expense recognized
amounted to $30,000 in 1999, and $387,895 in 2000. The fair market value of the
options granted is estimated on the date of the grant using the Black-Scholes
pricing model with the following weighted average assumptions: dividend yield of
0%, volatility of 2.521, risk-free interest rate of 5% - 5.5% and an expected
life of 2-3 years.
Options and warrants to purchase 936,000 and 460,000 shares of the Company's
Common Stock were outstanding at March 31, 2000 and 1999, respectively.
Options and warrants outstanding were not included in the computation of
diluted loss per common share because the effect would be antidilutive.
In January 2000, the board of directors approved the conversion of debt to
stock for (a) six board members' accrued director's fees, (b) accrued salary
for three officers of the Company, (c) loans to the Company from one of its
officers, and (d) unreimbursed expenses for one of the officers and one of
the directors. The conversion was structured to pay 20% of the debt in cash,
and 80% of the debt to be converted into 524,226 shares of Company Common
Stock at $ .75 per share. The different between this value and fair value at
the date of the conversion were booked as debt financing cost. In addition,
the boards also approved an award of 734,562 shares of the Company's Common
Stock. Those shares were valued at fair value at the date of the award
granted and booked as expenses.
F-14
<PAGE>
9. INCOME TAXES
For Federal income tax purposes, approximately $4,600,000 of net operating loss
carryforwards exists to offset future taxable income. These carryforwards expire
in 2014. No tax benefit has been reported in the accompanying financial
statements, however, because management believes that there is at least a 50%
chance that the carryforwards will expire unused. Accordingly, at March 31,
2000, the $1,175,000 tax benefit of the cumulative carryforwards has been offset
by a valuation allowance of the same amount.
10. RELATED PARTY TRANSACTIONS
The Company has received unsecured advances of $79,367 from one of its officers.
(See Note 6)
The Company has also entered into consulting contracts with certain directors
as a means of inducing the directors to devote additional time and effort to
the Company over and above the time normally expected of a director. These
contracts provide for payments of $2,000 per month to each director under
contract, have no stated termination date but are cancelable by either party
on 30 days written notice. Amounts paid by the Company under these contracts
were approximately $128,000 during the year March 31, 2000. Amounts accrued
to these directors for their services for the year ended March 31, 2000 are
$6,000.
The Company purchased various chemicals, lab equipment, research material, and
start-up expenses from a related party. The purchase of chemicals, lab
equipment, research materials, and start-up expenses amounted to $34,000 and
$2,012 during the period ended March 31, 1999 and 2000, respectively.
11. COMMITMENTS AND CONTINGENCIES
EMPLOYMENT AGREEMENTS: In May 1998, the Company entered into a three-year
employment agreement with Dr. Adrian Joseph. Under the agreement, Dr. Joseph
will serve as the Chief Executive Officer of the Company. The employment
agreement automatically renews for succeeding terms of one year, subject to
prior notification of termination by either the Company or Dr. Joseph. Annual
compensation pursuant to the employment agreement is $240,000 per year, payable
monthly, subject to annual increases at the discretion of the Company's Board of
Directors. Dr. Joseph is also to receive an annual bonus equal to 10% of the
amount of annual Company profits which exceeds $300,000 over the Company's prior
year's profits. Under the agreement, Dr. Joseph was also granted an option to
purchase 100,000 shares of the Company's Common Stock at $1 per share. The
option can be exercised in lots of 10,000 shares or more during the term of the
employment agreement until the termination of employment by the Company with
cause or June 1, 2001 whichever sooner occurs.
F-15
<PAGE>
In June 1998, the Company entered into an employment agreement with Kay Barone.
Under the agreement. Ms. Barone serves as an Administrative Assistant to Dr.
Adrian Joseph. Under the terms of that agreement, Ms. Barone will receive an
annual salary of $36,000.
In June 1998, the Company entered into an employment agreement with Sharon
Nitka. Ms. Nitka serves as the Chief Financial Officer of the Company. Under
the terms of that agreement, Ms. Nitka receives an annual salary of $42,000.
Sharon Nitka is the sister of Dr. Adrian Joseph, the Chief Executive Officer of
the Company.
In March 2000, the Company entered into an employment agreement with William
Wilson. Under the agreement, Mr. Wilson will serve as the President of the
Company until August 31, 2000 wherein the agreement automatically renews for
succeeding terms of six months. Under the terms of the agreement, Mr. Wilson
will receive an annual salary of $144,000 and stock option to purchase 250,000
shares of the Company's Common Stock at $.75 per share. The option can be
exercised on the anniversary date of each year of employment commencing the year
of employment. Also under the agreement, Mr. Wilson will receive 100,000
shares of the Company's Common Stock at the end of every 6 month period of
employment, with the first issuance of shares made on or before August 31,
2000 and every 6 months thereafter during the term of agreement.
CONSULTING AGREEMENTS: In June 1999, the Company entered into a consulting
agreement with Dr. Chong Chiu. Under the agreement, Dr. Chiu will provide
certain marketing, product development, specification review and other
services to the Company related to nuclear power plants. Dr. Chiu is the
former Engineering and Safety Manager of the San Onofre Nuclear Generating
Station. The agreement provides for Dr. Chiu to receive 15% percent of net
(amount received after cost of production) of all nuclear power plant
revenues generated as a direct result of his services. He is also to receive
10% of the gross value of the grants he generates for the Company and 400,000
shares of the Company's Common Stock over 3 years. In December 1999, pursuant
to the consulting agreement, the Company issued 134,000 shares of Company's
Common Stock to Dr. Chiu. These shares were valued at $2.20 per share.
Additional 133,000 shares each of the Company's Common Stock will be issued
to Dr. Chiu on or before December 15, 2000 and 2001, respectively.
In June 1999, the Company entered into a consulting agreement with National
Capital Merchant Group, Ltd. ("National Capital"). Under the agreement, National
Capital will provide advice, consultation, information, and services to the
Company regarding general financial and business matters such as mergers and
acquisitions, capital investitures, maintaining shareholder value, report on the
general financial markets, and investment banking services until June 30, 2000.
Under the terms of the agreement, National Capital received options to
purchase 40,000 shares of the Company's Common Stock at $2.50 per share. As of
March 31, 2000, National Capital exercised the option to purchase 30,000 shares
of the Company's Common Stock and received 10,000 shares from Dr. Joseph,
effectively canceling the agreement between the Company and National Capital.
The shares transferred from Dr. Joseph to National Capital were booked as
consulting fees.
In April 1999, the Company entered into a consulting agreement with Robert Shaw.
Under the agreement, Mr. Shaw will provide services to the Company such as
marketing analysis, marketing plan, and product development. Under the terms of
the agreement, Mr. Shaw will receive 15,000 shares option per month for his
services, which can be exercised at $1 per share of the Company's Common Stock
for 24 months commencing April 1, 1999.
F-16
<PAGE>
In June 1998, the Company entered into a consulting agreement with John
Longenecker. Under the agreement, Mr. Longenecker will provide services to
the Company as a member of the board of directors. Under the terms of the
agreement, Mr. Longenecker will receive an initial retainer fee of $7,000 and
$2,000 per month plus any out of pocket expenses incurred.
In December 1999, the Company entered into a consulting agreement with Shelby
Brewer. Under the agreement, Mr. Brewer will provide services to the Company
as a member of the board of directors. Under the terms of the agreement, Mr.
Brewer will receive $2,000 per month plus any out of pocket expenses
incurred. Pursuant to the agreement, Mr. Brewer also received options to
purchase 200,000 shares of the Company's Common Stock at $2 per share.
INDEMNIFICATION AGREEMENT: In September 1998, the Company entered into an
agreement with the Company's directors and officers (collectively "Indemnitees")
to hold, at the Indemnitee's request, the Indemnitee harmless from any and all
losses and expenses incurred by the Company. Furthermore, if the Company fails
to defend the Indemitee in a timely manner, the Company agrees to reimburse the
Indemnitee for expenses and losses incurred by the Indemnitee.
OPERATING LEASES: In June 1999, the Company moved to a new location and entered
into a three year lease that requires minimum monthly payments of $3,679 for
year one, $3,786 for year two, and $3,893 for year three. Rent expense for the
period ended March 31, 2000, was $40,469. In August 1999 the Company entered a
lease agreement for a postage meter for 42 months at $70 per month.
The estimated future minimum lease payments under all operating leases are as
follows:
Years Ending
March 31,
----------------------
2000 $ 45,737
2001 47,021
2002 20,305
2003 170
2004 --
---------------
Total $ 113,233
===============
12. RESTATEMENTS AND RECLASSIFICATIONS OF FINANCIAL STATEMENTS ENDED MARCH 31,
1999
The accompanying financial statements for the period ended March 31, 1999 have
been restated to correct errors in application of accounting principles in the
following transactions:
a. The Technology transferred to the Company from Dr. Joseph was valued
at $10,000. It should have been valued at zero basis. (See Note 3)
F-17
<PAGE>
b. Options granted to non-employees were not valued in accordance to SFAS
No. 123. (See Note 8)
c. There was no disclosure for stock granted to employees (SFAS No. 123)
in the prior year's financial statements.
The effect of the restatements increased net loss for the year ended March 31,
1999 by $30,000.
Interest expense for the period ended March 31, 1999 has been reclassified from
general and administrative expense to interest expense.
13. SUBSEQUENT EVENTS
STOCK OPTIONS: In April 2000, the Company entered into a public relations
agreement with International Media Solutions, Inc. Under that agreement,
International Media Solutions, Inc. is entitled to 100,000 shares of Common
Stock at $.25 per share on May 1, 2000 and 50,000 shares of Common Stock at
$2.00 per share on November 1, 2000.
Should the average bid price of the Common Stock five days prior to the
execution date be above $5 per share, said options shall be executed at a
price of $3.00. Should the average bid price of the Common Stock five days
prior to the execution date be above $7 per share, said options shall be
executed at a price of $4. The Company has agreed to allow International
Media Solutions, Inc. to forward the funds for the Common Stock as the shares
cross into the market.
CONSULTING AGREEMENT: In June 2000, the Company entered into a consulting
agreement with Robert Merriman. Under the agreement, Mr. Merriman will
provide services to the Company as a member of the board of directors.
Pursuant to this agreement, the Company will issue 300,000 shares of the
Company's Common Stock and an option to purchase up to 200,000 shares of the
Common Stock at $2 per share. Also, Mr. Merriman will receive $2,000 per
month plus any out of pocket expenses incurred.
NOTES PAYABLE: The Company has entered into an agreement with a private party
to obtain $450,000 in two year notes, interest payable semi-annually, with a
10% front end discount. As of June 2000, the Company has received in total of
$225,000 (net to the Company costs).
LEGAL PROCEEDINGS: Biltmore Advisors, LLC claims breach of an oral
contract and seeks specific performance or damages estimated to be
approximately $600,000. The Company has decided to vigorously defend this
matter. Although the case is at the beginning of the discovery process, there
has been an inquiry by counsel for the plaintiff to enter into settlement
negotiations for purposes of resolving the issue. The management of the
Company believes that the suit is without merit.
The Company has given sixty days notice of its termination of its
relationship with Dutchess Advisors, Ltd. However, Dutchess is raising
certain issues regarding compliance with the conditions of the agreement. The
Company agreed to grant Dutchess an option to purchase 34,000 shares of the
Company's Common Stock which were valued at fair market value.
F-18
<PAGE>
PART III
INDEX TO EXHIBITS AND DESCRIPTION OF EXHIBITS.
The following exhibits are included as part of this Report:
EXHIBIT NO. DESCRIPTION
----------- -----------
2.1 Articles of Incorporation, as amended(1)
2.2 Bylaws(1)
3.1 Form of Class "A" Common Stock Purchase Warrant
Certificate(1)
3.2 Form of Class "B" Common Stock Purchase Warrant
Certificate(1)
3.3 Form of $385,000 Series 1999-A Convertible Promissory Note
due December 1, 2001(2)
3.4 Form of $385,000 Series 2000-A Convertible Promissory Note
due December 1, 2001
3.5 Form of Warrant issued to Triton Private Equities Fund, L.P.
on December 15, 1999 (2)
3.6 Form of Warrant issued to Triton Private Equities Fund, L.P.
on February 8, 2000
6.1 Employment Agreement between the Company and Adrian A.
Joseph, Ph.D. dated May 15, 1998(1)
6.2 Sale of Technology between the Company and Adrian A. Joseph
dated June 12, 1998(1)
6.3 Employment Agreement between the Company and Sharon Nitka
dated June 1, 1998(1)
6.4 Consulting Agreement between the Company and John
Longenecker dated June 26, 1998(1)
6.5 Consulting Agreement between the Company and William A.
Wilson dated June 10, 1998(1)
6.6 Consulting Agreement between the Company and Rita Lavelle
dated June 1, 1998(1)
6.7 Form of Stock Option Agreement between the Company and its
officers and directors(1)
6.8 1998 Stock Option Plan(1)
6.9 Form of Indemnification Agreement between the Company and
its officers and directors(1)
III-1
<PAGE>
6.10 Letter of Understanding for Proposed Agreement Between the
Company and Performance Improvement International dated
March 1, 1999(3)
6.11 Research Plan submitted by the University of Missouri to the
Company(3)
6.12 Consulting Agreement between the Company and Dr. Chong Chiu
dated June 25, 1999 (4)
6.13 Investment Banking Services Agreement between the Company
and National Capital Merchant Group, Ltd. dated June 30,
1999 (4)
6.14 Employment Agreement between the Company and Harold L. Rapp
dated August 6, 1999 (5)
6.15 Securities Purchase Agreement between the Company and Triton
Private Equities Fund, L.P. dated December 15, 1999 (2)
6.16 Securities Purchase Agreement between the Company and Triton
Private Equities Fund, L.P. dated February 8, 2000
6.17 Registration Rights Agreement between the Company and Triton
Private Equities Fund, L.P. dated December 15, 1999 (2)
6.18 Registration Rights Agreement between the Company and Triton
Private Equities Fund, L.P. dated February 8, 2000
6.19 Promissory Note dated April 6, 2000 for $165,000 from the
Company to the Glenn A. Cramer Separate Property Trust
6.20 Promissory Note dated May 1, 2000 for $82,500 from the
Company to the Glenn A. Cramer Separate Property Trust
6.21 Promissory Note dated June 1, 2000 for $82,500 from the
Company to the Glenn A. Cramer Separate Property Trust
6.22 Consulting Agreement between the Company and Shelby T.
Brewer dated December 1, 1999
6.23 Employment Agreement between the Company and William Wilson
dated March 1, 2000
6.24 Consulting Agreement between the Company and Robert
Merriman dated as of June 9, 2000
12 Power of Attorney
27 Financial Data Schedule
------------
(1) Incorporated by reference from the Company's Registration
Statement on Form 10-SB (File No. 0-25377). Exhibit numbers from
that Registration Statement have been retained.
(2) Incorporated by reference from the Company's Report on Form
10-QSB for the quarter ended December 31, 1999 (File No. 0-25377)
(3) Incorporated by reference from Amendment No. 1 to the Company's
Registration Statement on Form 10-SB (File No. 0-25377). Exhibit
numbers from that Registration Statement have been retained.
(4) Incorporated by reference from the Company's Report on Form
10-QSB for the quarter ended June 30, 1999 (File No. 0-25377)
(5) Incorporated by reference from the Company's Report on Form
10-QSB for the quarter ended September 30, 1999 (File No.
0-25377)
III-2
<PAGE>
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
has caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Newport Beach, State of California, on the 11th
day of July, 2000.
NURESCELL INC.
By: /s/ ADRIAN A. JOSEPH
-------------------------------------------
Adrian A. Joseph, Chief Executive Officer
Principal Executive Officer
By: /s/ SHARON NITKA
-------------------------------------------
Sharon Nitka, Chief Financial Officer
Principal Financial and Accounting Officer
In accordance with the Exchange Act, this report has been signed below by
the following persons on behalf of the Registrant and in the capacities and on
the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
/s/ WILLIAM A. WILSON President and Chairman of the Board July 11, 2000
-------------------------
*William A. Wilson
/s/ SHELBY T. BREWER Director July 11, 2000
-------------------------
*Shelby T. Brewer
/s/ JOHN R. LONGENECKER Director and Vice President - Operations July 11, 2000
-------------------------
*John R. Longenecker
/s/ ROBERT MERRIMAN Director July 11, 2000
-------------------------
*Robert Merriman
/s/ SHARON NITKA Director, Chief Financial Officer and Secretary July 11, 2000
-------------------------
Sharon Nitka
</TABLE>
*By: /s/ SHARON NITKA
--------------------
Sharon Nitka,
Attorney-in-Fact
III-3
